Literature DB >> 11480850

Infections in outpatients with systemic lupus erythematosus: a prospective study.

A Zonana-Nacach1, A Camargo-Coronel, P Yañez, L Sánchez, F J Jimenez-Balderas, A Fraga.   

Abstract

The objective of this study was to assess the incidence and risk factors of infections in 200 SLE outpatients. All outpatients with active or inactive SLE without infections in the previous month were included. They were assessed every 3 months. Major infections were those requiring hospitalization and parental antibiotic therapy; minor infections required oral or topical therapy. Sociodemographic, disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), therapy and laboratory variables were evaluated. After a follow-up of 22+/-7 months, 65 (32%) patients had infections; 35% of those were major. The most common sites for infection were urinary (26%), skin (23%), systemic (12%), and vaginal (9%). At infection onset, 50 of 65 patients (77%) had disease activity, with a mean SLEDAI score of 6.1. The variables significantly associated with infection in the univariate analyses were the presence of disease activity, SLEDAI score, renal activity, prednisone dose, and IV cyclophosphamide. The only variable associated with infection in the multivariate analyses was a SLEDAI score of 4 or higher. Most infections in SLE outpatients were single, minor, non-life threatening, and associated with disease activity independently of sociodemographic and therapeutic factors.

Entities:  

Mesh:

Year:  2001        PMID: 11480850     DOI: 10.1191/096120301678416088

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  20 in total

1.  Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.

Authors:  Petar Lenert; Adam Goeken; Barry S Handwerger; Robert F Ashman
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

Review 2.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 3.  Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  Prevalence of Chlamydia trachomatis endocervical infection in systemic lupus erythematosus patients and evaluation of the risk for HPV-induced lesions.

Authors:  Licia CostaPinto; Viviana Gallazzi Olavarria; Maria Fernanda Rios Grassi; Leomar D' Cirqueira Lyrio; Rone Peterson Cerqueira Oliveira; Iuri Usêda Santana; Cristiane Bahiana Cruz; Mittermayer Barreto Santiago
Journal:  Rheumatol Int       Date:  2012-04-07       Impact factor: 2.631

5.  Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.

Authors:  Candace H Feldman; Linda T Hiraki; Wolfgang C Winkelmayer; Francisco M Marty; Jessica M Franklin; Seoyoung C Kim; Karen H Costenbader
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

6.  Presence of antibodies to SSB/La is associated with decreased phagocytic efficiency of neutrophils in patients with systemic lupus erythematosus.

Authors:  Debasis Biswas; Amrita Mathias; Rajeshwar Dayal; Amita Aggarwal; Ramnath Misra; Sita Naik
Journal:  Clin Rheumatol       Date:  2007-11-06       Impact factor: 2.980

7.  In-hospital mortality in patients with systemic lupus erythematosus: a study from Jordan 2002-2017.

Authors:  Marwan H Adwan; Ula Qasem; Khader N Mustafa
Journal:  Rheumatol Int       Date:  2020-03-07       Impact factor: 2.631

Review 8.  SLE and infections.

Authors:  Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

9.  Predictors of major infections in systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Nerea Olivares; Ioana Ruiz-Arruza; Agustin Martinez-Berriotxoa; Maria-Victoria Egurbide; Ciriaco Aguirre
Journal:  Arthritis Res Ther       Date:  2009-07-15       Impact factor: 5.156

10.  Low incidence of opportunistic Infections in Lupus Patients treated with Cyclophosphamide and Steroids in a Tertiary care setting.

Authors:  Shubhasree Banerjee; Ann Biehl; Maryam Ghaderi-Yeganeh; Zerai Manna; Sarfaraz Hasni
Journal:  Med Res Arch       Date:  2017-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.